一种具有血管作用的新型原创口服抗糖尿病药物：格列齐特（SE - 1702）的治疗价值 - Suppr | 超能文献

[Therapeutic value of a new original oral antidiabetic with vascular action: gliclazide (SE-1702)].

作者信息

Canivet J

出版信息

Therapeutique. 1972 Sep-Oct;48(7):457-62.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Therapeutic value of a new original oral antidiabetic with vascular action: gliclazide (SE-1702)].一种具有血管作用的新型原创口服抗糖尿病药物：格列齐特（SE - 1702）的治疗价值

Therapeutique. 1972 Sep-Oct;48(7):457-62.

2

[Study on Gliclazide, an antidiabetic with a double vascular and metabolic polarity].[格列齐特的研究，一种具有双重血管和代谢极性的抗糖尿病药物]

Mars Med. 1972;109(10):655-8.

3

[The real problem in diabetes (trial of gliclazide, an original molecule with metabolic and vascular properties)].

Therapeutique. 1972 Nov;48(9):569-73.

4

[Significance of an oral antidiabetic with vascular action: gliclazide in the asymptomatic diabetes and patent diabetes].

Journ Annu Diabetol Hotel Dieu. 1976 May:331-9.

5

[Therapeutic value of a new oral antidiabetic agent: gliclazide].

Clin Ter. 1978 Mar 31;84(6):627-35.

6

[Therapeutic trial of a new antidiabetic with vascular action: 1702 SE].[一种具有血管作用的新型抗糖尿病药物的治疗试验：1702 SE]

Lille Med. 1972 Oct;17(9):Suppl 6:1332-6.

7

[Therapeutic value of a new hypoglycemic agent (gliclazide) in the treatment of diabetes mellitus].

Clin Ter. 1978 Jan 31;84(2):135-40.

8

[Gliclazide, a new antidiabetic with hemobiologic and vascular properties].[格列齐特，一种具有血液生物学和血管特性的新型抗糖尿病药物]

Lyon Med. 1972 Oct 22;228(16):383-5.

9

[Clinical trial with a new oral antidiabetic, gliclazid, in general practice (author's transl)].

Schweiz Rundsch Med Prax. 1982 Apr 20;71(16):699-704.

10

[Effect of insulin and sulfonylurea derivatives on chronic intravascular microcoagulation of the blood in diabetes mellitus].

Sov Med. 1985(9):91-3.

引用本文的文献

1

Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.格列齐特。对其药效学特性及在糖尿病治疗中的疗效的初步综述。

Drugs. 1984 Apr;27(4):301-27. doi: 10.2165/00003495-198427040-00002.